⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16637138 | 1.00 | — | — | |
| SCHEMBL22028855 | 0.86 | HSP90AA1 (0.32) | — | |
| SCHEMBL29617699 | 0.86 | HSP90AA1 (0.32) | — | |
| SCHEMBL26623643 | 0.83 | — | — | |
| SCHEMBL21379233 | 0.83 | — | — | |
| SCHEMBL29592633 | 0.83 | — | — | |
| SCHEMBL31470359 | 0.83 | — | — | |
| SCHEMBL29343951 | 0.83 | — | — | |
| SCHEMBL25987673 | 0.83 | HTT (0.42) | — | |
| SCHEMBL27426463 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4655298-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | Theras Inc. (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4584276-A1 | KRAS G12D INHIBITORS | Bristol-Myers Squibb Company (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250179077-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2025-06-05 | — | — | US | disclosed |
| CN-120092011-A | KRAS G12D inhibitors | 百时美施贵宝公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-119998275-A | KRAS inhibitors | 百时美施贵宝公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-119790059-A | Heterocyclic compounds as KRAS inhibitors, their preparation and therapeutic use | 上海科州药物股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119677726-A | KRAS inhibitors | 百时美施贵宝公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-119591588-A | RAS inhibitors | 泰励生物科技（上海）有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20250059208-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-02-20 | — | — | US | disclosed |
| CN-115201485-A | Methods of measuring KRAS protein inhibition | 百济神州(北京)生物科技有限公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-115181106-A | Quinazoline KRAS G12D Preparation and application of mutant protein inhibitor | 药雅科技(上海)有限公司 | 2022-10-14 | — | — | CN | disclosed |
| EP-4065583-A1 | A COMPOUND HAVING INHIBITORY ACTIVITY AGAINST KRAS G12D MUTATION | Taiho Pharmaceutical Co., Ltd. (JP) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022184178-A1 | KRAS G12D INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-09-09 | — | — | WO | disclosed |
| CN-115003677-A | Compounds having inhibitory activity against KRAS G12D mutation | 大鹏药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| WO-2022177917-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2022-08-25 | — | — | WO | disclosed |
| WO-2022098625-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-05-12 | — | — | WO | disclosed |
| CN-110267957-B | Quinazoline compounds | 安斯泰来制药株式会社 | 2022-04-26 | — | — | CN | disclosed |
| CN-114222743-A | Oxoaxamembered ring pyrimidine compounds, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2022-03-22 | — | — | CN | disclosed |
| WO-2022047093-A1 | VINYL IMIDAZOLE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2022-03-03 | — | — | WO | disclosed |